OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson Sells 15,526 Shares

OmniAb, Inc. (NASDAQ:OABI) CFO Kurt A. Gustafson sold 15,526 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total transaction of $50,304.24. Following the completion of the transaction, the chief financial officer now owns 212,720 shares of the company’s stock, valued at $689,212.80. This trade represents a 6.80 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

OmniAb Price Performance

NASDAQ:OABI opened at $3.20 on Friday. The company’s 50-day moving average price is $3.66 and its two-hundred day moving average price is $4.06. OmniAb, Inc. has a 12 month low of $3.11 and a 12 month high of $6.55. The firm has a market cap of $451.89 million, a PE ratio of -5.16 and a beta of -0.10.

Institutional Investors Weigh In On OmniAb

Several hedge funds and other institutional investors have recently made changes to their positions in OABI. Dimensional Fund Advisors LP boosted its position in shares of OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after purchasing an additional 194,835 shares during the last quarter. Rice Hall James & Associates LLC raised its holdings in shares of OmniAb by 6.4% during the third quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after acquiring an additional 163,038 shares during the period. State Street Corp lifted its holdings in shares of OmniAb by 1.7% in the third quarter. State Street Corp now owns 2,031,676 shares of the company’s stock valued at $8,594,000 after purchasing an additional 34,654 shares in the last quarter. Murchinson Ltd. acquired a new position in OmniAb during the 3rd quarter worth approximately $4,230,000. Finally, Woodstock Corp grew its position in OmniAb by 1.2% in the fourth quarter. Woodstock Corp now owns 802,578 shares of the company’s stock valued at $2,841,000 after purchasing an additional 9,725 shares in the last quarter. 72.08% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

OABI has been the subject of a number of analyst reports. Benchmark reaffirmed a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reiterated a “buy” rating and issued a $11.00 target price on shares of OmniAb in a research note on Thursday, November 14th.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.